MedTrace Logo

"The Effects of Oxytocin on Patients With Borderline Personality Disorder"

NCT01243658 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2022-11-03

No results posted yet for this study

Summary

RCT. Two substudies (clinical and experimental). Main objective of the trial is to examine if oxytocin, compared to placebo shows any additional effect on the therapy achievements (outcome) of patients with borderline personality disorder, who receive an in-patient standard psychotherapy (Dialectical-behavioral-therapy, Marsha Linehan (2006)).

Secondary objectives :

Investigate if oxytocin compared to placebo enhances social trust and emotion recognition in patients with borderline personality disorder. Comparison of the effects of Oxytocin on patients with BPD and major depression.

Conditions

  • Effects of Oxytocin on Borderline Personality Disorder
  • Borderline Personality Disorder

Interventions

DRUG

Oxytocin

Oxytocin

OTHER

placebo

placebo

Sponsors & Collaborators

  • Prof. Dr. Markus Heinrichs

    lead OTHER

Principal Investigators

  • Markus Heinrichs, Prof. Dr. · Institut für Psychologie der Univeristät Freiburg

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2021-04-30
Completion
2022-04-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01243658 on ClinicalTrials.gov